Study study type PathologyT1T0Patientssample sizesROB Results

mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population

versus Standard of Care (SoC)
pembrolizumab alone
KEYNOTE-040 (all population), 2018
  NCT02252042
RCTmHNSCC - L2 - all populationpembrolizumabchemotherapy (methotrexate, docetaxel or cetuximab)patients with recurrent or metastatic head and neck squamous cell cancer that progressed during or after platinum-containing treatment : all population247 / 248some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)